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chronic lymphocytic leukemia | NOTCH1 | transcriptional network C hronic lymphocytic leukemia (CLL) is a common hematologic tumor characterized by the clonal expansion of CD5 + B cells (1, 2) . Recent investigations have provided a comprehensive picture of the CLL genome, revealing its relatively low burden of genetic lesions, with a small number of frequently mutated "driver" genes. CLL mutated genes include the NOTCH1 oncogene, the splicing regulator SF3B1, the tumor-suppressors TP53 and ATM, and several B-cell receptor (BCR)/NF-κB regulators, such as MYD88, BIRC3, and NFKBIE, among others (3) (4) (5) (6) (7) .
NOTCH1, a well-known oncogene in T-cell acute lymphoblastic leukemia (T-ALL) (8, 9) , has emerged as the most commonly mutated gene in CLL at diagnosis, accounting for ∼4-13% of patients (3) (4) (5) (6) (7) . NOTCH1 encodes a transmembrane receptor that, upon binding to a ligand expressed on the surface of a "signalsending" cell, undergoes a series of conformational changes and proteolytic cleavages, ultimately allowing the translocation of its intracellular, cleaved, and active portion (hereinafter referred to as "ICN1") to the nucleus (10, 11) . Once in the nucleus, ICN1 binds to the DNA-binding protein RBPJ, the main effector of NOTCHsignaling, and recruits a series of coactivator proteins to induce transcriptional activation of target genes (10, 11) . NOTCH1 target genes mediate regulation of fundamental biological processes, such as development, cell differentiation, cell-fate decision, proliferation, and apoptosis (10, 11) .
In contrast to T-ALL, where the majority of mutations are represented by constitutively activated ligand-independent alleles affecting the heterodimerization domain of the protein, most NOTCH1 mutational events in CLL are represented by PEST [proline (P), glutamic acid (E), serine (S), threonine (T)-rich protein sequence] -truncations removing the phosphodegron sequence required for FBXW7-mediated ICN1 proteasomal degradation; in a minority of cases, point mutations in the 3′UTR of the NOTCH1 mRNA lead to aberrant splicing events that also remove the PEST domain of the NOTCH1 protein (3) (4) (5) (6) (7) . NOTCH1 mutations in CLL were shown to associate with poor prognosis, including a specific subset of patients carrying trisomy 12, disease progression, transformation to highly aggressive diffuse large B-cell lymphomas, termed Richter syndrome, and immunochemotherapy resistance (3, 4, (12) (13) (14) (15) (16) .
Despite this potentially relevant role in the CLL clinical course, the oncogenic role of NOTCH1 in this disease remains poorly understood. Although few NOTCH1 targets have been shown to be overexpressed in NOTCH1-mutated cases compared with wild-type CLL (4, 17, 18) , the full spectrum of genes controlled by NOTCH1 and their contribution to the disease pathogenesis have not been identified. Moreover, recent reports documented that CLL cells in the lymph node frequently express ICN1, independent of NOTCH1 PEST-truncation (19, 20) , especially within the proliferation centers, which represent the key microanatomical sites of interaction of CLL cells with accessory cells and proliferation (21) . Accordingly, these findings have been interpreted as the result of microenvironmental signals activating the NOTCH1 cascade. Conversely, the status of NOTCH1 Significance A pathogenetic role of NOTCH1 in chronic lymphocytic leukemia (CLL) has been implied by the presence of deregulating mutations in a relatively small fraction of cases. Our results now indicate that ∼50% of CLL cases devoid of mutations express the active form of NOTCH1 ICN1 (intracellular portion of NOTCH1), thus implicating a much broader role of this transcription factor in the disease. ICN1
+ CLL cases display equivalent NOTCH1-dependent transcriptional responses regardless of the gene mutation status, indicating that the detection of ICN1 represents a reliable biomarker of NOTCH1 activation for diagnostic and therapeutic targeting. Finally, our results identify the NOTCH1-dependent transcriptional program in CLL cells, thus providing direct insights into the pathogenesis of a large fraction of CLL cases. activation in the peripheral blood (PB) compartment of CLL patients is less clear (4, 7, 18, 22) .
To address these questions, we have analyzed the functional status of ICN1 in normal mature B cells and in a panel of PB CLL cells including both NOTCH1-mutated and wild-type cases. We report broader NOTCH1 activation, significantly extending beyond the mutated cases and the transcriptional consequences of this activation in leukemic B cells.
Results

NOTCH1
Is Activated in Naïve and Memory B Cells, the Putative Normal Counterparts of CLL. To obtain a comparative baseline before investigating the activity of NOTCH1 in CLL, we first defined the expression and activation pattern of NOTCH1 in normal mature B-cell subsets. We performed gene-expression profiling as well as ICN1 immunoblot analysis in naïve, germinal center (GC) and memory B cells isolated from human tonsils (23) . Although the phenotype of the B cell expanding to generate overt CLL remains a matter of debate, naïve and memory B cells are considered the most likely putative normal counterparts of this disease (24) (25) (26) . The levels of NOTCH1 mRNA and of the cleaved and active intracellular portion of NOTCH1 ICN1 were abundant in naïve and memory B cells, whereas they were almost undetectable in GC B cells ( Fig. 1 A and B) . Immunofluorescence staining of human tonsillar biopsies confirmed these findings, revealing ICN1 nuclear staining in the B-cell fraction populating the mantle zone of the GCs, which is highly enriched in naïve B cells ( Fig. 1C and Fig. S1 ).
Gene set enrichment analysis (GSEA) using the "Hallmark_ Notch_Signaling" signature from the Molecular Signature Database (27) confirmed that ICN1 expression in naïve and memory B cells is associated with NOTCH1 transcriptional activity (Fig.  1D) . Taken together, these data indicate that NOTCH1 is physiologically expressed and activated in the cells of origin of CLL.
PB CLL Cells Express ICN1 in both NOTCH1-Mutated and Wild-Type Cases. We next investigated the incidence of NOTCH1 pathway activation in CLL by analyzing peripheral blood CLL cells (>70% purity in 90 of 93 cases analyzed by cytofluorimetry analysis for CD5 + /CD19 + ) (Materials and Methods) from a cohort of primary CLL cases (n = 124). Twenty-two percent of these cases carried NOTCH1 PEST-truncating events (n = 27 of 124) (Dataset S1), representative of the prototypical p.P2515fs mutation (n = 17 of 29, 58.6%), frameshift deletions (n = 3 of 29, 10.3%), and nonsense mutations (n = 5 of 29, 17.2%). In addition, four cases carried 3′UTR NOTCH1 mutations known to lead to aberrant splicing events disrupting the PEST domain of the ICN1 protein (7) . The majority of NOTCH1-mutated CLL cases carried unmutated IGHV genes (n = 23 of 24 with known IGHV status, 95.8%), as previously reported (3, 4, 12) .
Notably, ICN1 was detectable by immunoblot analysis in 50.5% (n = 49 of 97) of NOTCH1-wild-type cases ( Fig. 2 A and  B and Fig. S2A ). Among these, ICN1 expression occurred in 53.3% (n = 24 of 45) of IGHV mutated and 41.9% (n = 13 of 31) of IGHV-unmutated cases, respectively (Dataset S1).
As expected, all NOTCH1 PEST-disrupted CLL cases expressed a truncated active form of the protein (Fig. 2 A and B and Fig. S2A ) (4, 7) . The levels of ICN1 expression were variable across the panel, with NOTCH1-mutated cases often displaying higher levels of ICN1 compared with wild-type samples (Fig. S2A ). ICN1 levels in NOTCH1-wild-type cases were responsive to NOTCH inhibition by the γ-secretase inhibitor Compound-E (28) (Fig. S2B) .
Immunofluorescence analysis showed that strong nuclear ICN1 expression was detectable in virtually 100% of CLL cells in both NOTCH1-mutated and wild-type ICN1 + CLL cases (Fig. 2C ). Moreover, ICN1 was not expressed in PB mononuclear cells (PBMCs) from healthy, age-matched elderly individuals (Fig. S2C ). These observations exclude the possibility that ICN1 expression in NOTCH1-wild-type cases was because of residual contamination by normal cells. Altogether, these results suggest that the activation of the NOTCH1 oncogene in CLL is more common than what is currently known based on the frequency of NOTCH1 activating mutations (Discussion).
Identification of the CLL NOTCH1-Direct Transcriptional Program. As a tool to further interrogate the functional activity of NOTCH1 in ICN1
+ CLL cells and to shed light on the NOTCH1-controlled biological functions in CLL, we next investigated the NOTCH1-dependent CLL transcriptional program. We used a CLL cell line (MO1043) (29) , which carries a hemizygous NOTCH1 PESTtruncation and expresses a truncated ICN1 that is responsive to NOTCH inhibition by the γ-secretase inhibitor Compound-E (28). Given the low intrinsic signaling activity of PEST-truncated alleles alone (8) (Fig. S3A) , we sought to investigate NOTCH1-dependent programs using an inducible lentiviral system expressing either an HA-tagged constitutively active form of NOTCH1 (ICN1-HA) or control eGFP upon doxycycline addition (Fig. S3B) (30) . Induction of NOTCH1 signaling was demonstrated by HA immunoblot and quantitative RT-PCR (qRT-PCR) for DTX1, a well-established NOTCH1-direct target gene (11) (Fig. S3 C-E). This experimental system was used to identify genetic elements bound and directly regulated by NOTCH1 by integrating RNA-Seq and NOTCH1 ChIP-Seq data (Datasets S1-S3). Unsupervised clustering of RNA-Seq data showed that the expression profiles of MO1043-ICN1-HA and -eGFP cells cluster separately (Fig. 3A) . Supervised analysis revealed that ICN1-HA induction leads to up-regulation of over 700 transcripts [falsediscovery rate (FDR) < 0.001, median fold-change 1.7, range = 1.1-170.4], including known NOTCH1 targets, such as HES/HEY family members, NRARP, DTX1, and NOTCH1 itself, as expected ( Fig. 3B) , as well as genes involved in immune and signaling pathways relevant for the development and activation of B cells (Datasets S4 and S5).
ChIP-Seq analysis identified a total of 4,737 NOTCH1 binding sites, mapping to promoters in ∼40% of the cases, and to intragenic or distal regulatory regions of the genome in ∼60% of the cases ( Fig. 3 C and D) . The integration of NOTCH1 ChIPSeq profiles with those of the H3K4me3, H3K4me, H3K27Ac, and H3K27me3 histone modifications ( Fig. S4 ) revealed that ∼94% of NOTCH1 proximal binding sites displayed chromatin marks characteristic of active promoters, whereas ∼37% of the distal ones were associated with putative active enhancers ( The intersection between the genes differentially expressed upon ICN1-HA induction as identified by RNA-Seq and the NOTCH1 binding profiles obtained through ChIP-Seq revealed a significant overlap between the two sets (P < 0.001), with ∼39% of genes induced by ICN1-HA (FDR < 0.001) being bound by NOTCH1 (Fig. 3I and Fig. S6) . Notably, genes associated with NOTCH1 binding sites in superenhancer regions were more often up-regulated upon ICN1-HA induction compared with those associated with NOTCH1 binding sites in other genomic regions (52% vs. 29%, P < 0.001) (Fig. S5C) . Motif enrichment analysis of sequences surrounding the NOTCH1 binding sites (±200 bp) and associated with significant (FDR < 0.001) up-regulation of the corresponding genes (n = 503) confirmed significant (P = 1.00E-15) enrichment of the DNA motifs of RBPJ, the main effector of NOTCH signaling (11) , as well as of binding sequences of other potential cooperating cofactors, including NF-κB, PU.1, ETS, and STAT family members ( Fig. 3J and Dataset S8).
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To determine whether NOTCH1-wild-type ICN1 + CLL cases display evidence of NOTCH1 signaling activation analogous to NOTCH1-mutated cases, we explored the presence of the NOTCH1 CLL signature identified above in RNA-Seq data from 49 PB CLL samples fully characterized in terms of NOTCH1 mutation and ICN1 protein expression. This panel included 10 NOTCH1-mutated cases expressing ICN1 (including three cases carrying NOTCH1 3′UTR events), 13 NOTCH1-wild-type cases expressing ICN1, and 26 cases devoid of both NOTCH1 mutations and ICN1 expression (Fig. S2A) . GSEA analysis (27) revealed significant enrichment of the NOTCH1 CLL signature both in NOTCH1-mutated (P = 0.002) and NOTCH1-wild-type (P = 0.04) cases expressing ICN1 compared with ICN1
− cases (Fig. 4A ). Leading edge genes (n = 90) determining a significant (P = 0.03) enrichment of the NOTCH1 CLL signature in ICN1 + cases were overall expressed at similar levels in NOTCH1-mutated and wildtype ICN1
+ cases [average fragments per kilobase of transcript per million mapped reads (FPKM) 54.3 and 51.3, respectively], with few genes expressed at higher levels in the NOTCH1-mutated ones (n = 9 of 90, P < 0.05) ( Fig. 4B and Dataset S10).
Thus, ICN1 is also functionally active in ICN1 + CLL cases devoid of NOTCH1 mutations, indicating that they are functionally equivalent in terms of NOTCH1-dependent transcriptional responses to NOTCH1-mutated ones (Discussion).
Regulates Genes with Key Functions in B-Cell Physiology.
Functional annotation of the full set of genes bound (ChIP-Seq) and dynamically connected (RNA-Seq) to NOTCH1 revealed that NOTCH1 directly regulates general functions involved in cell proliferation and survival (Datasets S11 and S12). The former included CCND3, which encodes a cyclin necessary for G1/G2 transition (39) via direct binding to the gene promoter, consistent with a previous report in T-ALL (40) . Among the latter, BCL2 and MCL1, two antiapoptotic genes with a well-established role in the pathogenesis of CLL, emerged as novel targets of NOTCH1, likely regulated through long-range dynamic interactions (24, (41) (42) (43) .
The NOTCH1 transcriptional program included also a cadre of genes with specific functions in B-cell physiology (Fig. S7 ). Among these are BCR signaling pathway genes, including upstream pathway members (e.g., LYN, SYK, BLK, BLNK, CR2, and PIK3CD), as well as downstream effectors, such as MAPK (e.g., MAP3K1, KRAS, and RRAS) and NF-κB cascade members (e.g., IKBKB, NFKB1, and the CBM signalosome complex member MALT1) (44) . NOTCH1 also appears to activate the NF-κB target NFKBIA, which encodes the NF-κB repressor IκBα (44) , and PTPN6, encoding SHP-1, an important negative modulator of antigen-receptor signaling in lymphocytes (45) , suggesting a role of NOTCH1 in a delayed negativefeedback of activation of this cascade (46) . CXCR4, which encodes a chemokine receptor relevant for the chemotaxis of CLL cells toward microenvironmental cells expressing the CXCL12 ligand (47), emerged as a novel NOTCH1 target in CLL. This axis is fundamental for the exit of CLL cells from lymph nodes and, accordingly, the expression of the CXCR4 receptor has been shown to associate with a higher risk of lymphoid organ infiltration and poor disease outcome (48) . Finally, among several NOTCH-pathway related genes, NOTCH1 induced the expression of JAG1, which encodes for a ligand of NOTCH1 reported to be expressed on the surface of CLL cells (22) , suggesting a positive feed-forward loop in signaling activation.
NOTCH1 Transactivates MYC in CLL. MYC is a central oncogene in human malignancy, an established NOTCH1 target in T-ALL and is involved in CLL progression (3, 13, (49) (50) (51) . Thus, we investigated the relationship between NOTCH1 activation and MYC gene expression in CLL. Consistent with previous reports (52), we observed two putative superenhancers located ∼500 kb upstream of the MYC oncogene both in MO1043-ICN1-HA cells and primary CLL cases (Fig. 5 A and B) . These superenhancers were also present in CD19 + and CD20 + B cells, small lymphocytic lymphoma, and mantle cell lymphoma (52), but not in the majority of ∼90 distinct tissue types (37), suggesting context specificity (Fig.  5C and Fig. S8A ). NOTCH1 ChIP-Seq analysis of MO1043-ICN1-HA cells revealed the presence of multiple NOTCH1 peaks and RBPJK conserved motifs in this region. Specifically, one superenhancer within region 8q24 (chr8:128191039-128239723, hg19) contained one NOTCH1 binding site and two RBPJK motifs, whereas a second one (chr8:128299403-128321023, hg19), contained four NOTCH1 binding sites and three RBPJK motifs (Fig.  5B) . Local ChIP analysis of NOTCH1 and the H3K27Ac mark in MO1043-ICN1-HA cells confirmed NOTCH1 binding at these epigenetically active superenhancers (Fig. 5D) .
Intriguingly, our meta-analysis of copy number (CN) data obtained in two independent collections of CLL patients (7, 53) revealed that this region is recurrently affected by duplications in CLL (n = 15 of 452 and n = 15 of 353), including focal ones specifically encompassing this superenhancer cluster (Fig. 5A and Fig.  S8 B and C), suggesting that these genetic lesions may affect MYC expression in CLL. Moreover, we observed that NOTCH1 mutations and MYC locus duplications, including those focally affecting only this superenhancer region, were largely mutually exclusive in primary CLL patients (7) (Fig. S8D) , similarly to CLL cells that have undergone Richter syndrome transformation (3, 13) .
To demonstrate a direct functional relationship between NOTCH1 and MYC in CLL, we first investigated whether NOTCH1 activation could promote MYC transcription in ICN1 − or ICN1-low primary CLL cells cocultured with stromal cells expressing the NOTCH1 ligand Delta-1 (OP9-DL1) (54) . CLL cells cocultured with OP9-DL1 cells showed an increased level of MYC RNA, which was specifically dependent upon NOTCH1 expression because it was abrogated in the presence of the NOTCH-inhibitor Compound E (Fig. 5E and Fig. S9 ). Reciprocally, NOTCH1 inhibition by Compound E induced MYC down-regulation in ICN1-positive CLL cases ( Fig. 5E and Fig. S9 ). These results indicate that NOTCH1 controls MYC expression in ICN1 + CLL cells.
Discussion CLL cells in the lymph node are known to display frequent NOTCH1 activation independent of mutation, as documented by their frequent immunohistochemical positivity for ICN1 in lymph node sections of both NOTCH1-mutated and wild-type cases (19, 20) . Conversely, few reports have shown activation of NOTCH1 in PB CLL samples, and the results involved a relatively low number of cases and a possibly low sensitivity of detection, leading to a significant underestimation of the ICN1 + cases (4, 7, 18, 22) . Our finding that ∼50% of PB CLL cases lacking NOTCH1 mutations express ICN1 strongly suggests that the activation of this pathway is more common than what is predicted by the frequency of classic NOTCH1 PEST-truncations. These findings have implications for the mechanisms leading to NOTCH1 activation in normal and transformed cells, for the understanding of the pathogenesis of CLL, and the development of anti-NOTCH1 targeted therapies.
Mechanisms of NOTCH1 Activation in PB CLL Cells. The common detection of ICN1 in the nucleus of CLL cells within lymph nodes in both NOTCH1-mutated and wild-type cases has been interpreted as an induction by microenvironmental interactions with cells expressing NOTCH1 ligands (19, 20) . Conversely, the frequent detection of ICN1 in NOTCH1-wild-type PB CLL cells shown herein raises the issue, shared also by NOTCH1-mutated cases carrying activationdependent alleles, of the mechanisms leading to signaling induction. Although it is plausible that CLL cells may continuously recirculate between the PB and secondary niches, such as the lymph nodes, thus being exposed to signals triggering NOTCH1 activation, several observations seem to disfavor the possibility that the ICN1 presence observed in these cells is because of residual signaling form the nodal environment. It has been shown that perinodal CLL cells rapidly lose nuclear ICN1 expression once they move beyond the lymph node capsule (19) . The half-life of ICN1 is short and variable, from less than an hour to a few hours in several tested cell types (55), including primary CLL cells, but it is significantly shorter than the long life of CLL cells in the PB, which has been estimated to be of at least several days (56) . These observations, together with the fact that ICN1 is expressed in virtually all CLL cells in ICN1 + cases (Fig. 2C ), are consistent with the continuous induction of the NOTCH1 cascade in CLL cells in the blood stream. However, future studies should compare ICN1 levels in the peripheral blood and in the nodal CLL compartment of the same individual to achieve a better understanding of the dynamics of ICN1 expression in different anatomic compartments within the same CLL patient.
It is conceivable that sustained NOTCH1 activation in the PB may be mediated by cell-autonomous and ligand-dependent mechanisms. Among the former, activation of alternative cryptic NOTCH1 promoters has been reported in human and, more frequently, murine T-ALL (57-59). However, this mechanism was preliminarily excluded by the analysis of H3K27Ac ChIP-Seq data in a panel of nine CLL cases, all of which displayed high levels of the H3K27Ac mark decorating only the canonical 5′ transcriptional start site (TSS) of the NOTCH1 gene (Fig. S10) . Additional ligand-independent mechanisms include activation by other signaling pathways, as reported for the T-cell receptor pathway in T cells (60) , or aberrant vesicle trafficking of the NOTCH1 receptor (61) . Ligand-dependent mechanisms include binding to ligands expressed by endothelial cells in the blood vessels or by the CLL cells themselves (18, 22 HES4  1  2  1  2  3  SE1  SE2  HES4  1  2  1  2  3  SE1 SE2 The enrichment of our NOTCH1 CLL signature in these normal subpopulations compared with GC B cells suggests that the biological programs orchestrated by NOTCH1 in CLL are similar to those already active in the putative normal B-cell counterparts of the disease. Thus, the finding of NOTCH1 activation in CLL cells reflects the constitutive, dysregulated expression of a physiologic signal and its corresponding gene-expression program rather than an ectopic program associated with transformation. The set of NOTCH1-direct transcriptional target genes suggests a broad program aimed at promoting the survival and proliferation of mature B cells by supporting BCR and cytokine signaling and their downstream effectors, such as PI3K and NF-κB pathways. NOTCH1 direct targets specifically relevant for the B-cell phenotype appear to be regulated via direct activation of the corresponding promoters, as well as via longrange interactions occurring at superenhancer sites, consistent with the role of these large regulatory elements in orchestrating the expression of cell-type specific genes (37).
Role of NOTCH1-Induced MYC Expression. An important component of the NOTCH1-controlled program in CLL cells is the transactivation of the MYC oncogene. Our data suggest that this transactivation is mediated by the binding of NOTCH1 to B-cell-specific superenhancers located ∼500 kb upstream of the MYC locus. This region interacts with the MYC promoter in small lymphocytic lymphoma and mantle cell lymphoma, and also leads to MYC transcriptional activation in Epstein-Barr-transformed lymphoblastoid cells as a result of Epstein-Barr virus nuclear antigen 2 binding (52, 62) . The focal recurrent duplications of this locus observed in CLL (7, 53) , analogous to what is observed in other malignancies in which CN gains affect the tissue-specific enhancers involved in MYC expression (50, 63, 64) , suggest that the gain of context-specific superenhancers represents a common mechanism for up-regulating MYC expression in distinct tumor types. However, the detection of this superenhancer cluster also in CLL cases devoid of ICN1 expression (Fig. 5A) , and the observation that MYC mRNA levels were not significantly different between ICN1 + and ICN1 − CLL cases indicate that other transcription factors are likely involved in the regulation of this locus in B cells, as previously suggested for EBF and RELA in EpsteinBarr-transformed lymphoblastoid cells (62) .
Clinical Implications. The observation that the NOTCH1 CLL signature is enriched in ICN1 + CLL cases independent of NOTCH1 mutation significantly increases the fraction of CLL cases that may be dependent on constitutive NOTCH1 activity. NOTCH1 mutations are known to associate with adverse CLL clinical and biological features, including an unmutated IGHV status (12) , and predict a poor outcome when found in CLL patients at diagnosis (12) . Conversely, our results showed that ICN1 expression in cases devoid of NOTCH1 mutations occurred at similar frequencies in IGHVmutated and IGHV-unmutated CLL cases. However, the relatively small and heterogeneous cohort of patients analyzed in this study did not provide us with the statistical power of establishing reliable correlations between ICN1 expression and the clinical course of the disease. Thus, dedicated prospective clinical studies are warranted to assess the biological and prognostic associations of ICN1 expression rather than NOTCH1 mutations in CLL alone, especially in the context of anti-CD20-based therapies. This analysis may allow further refinement of the recent mutation/cytogenetic hierarchical model of classification of patients with CLL in distinct risk classes (65) . Finally, we propose that ICN1 expression may also represent a more reliable biomarker of NOTCH1 activation in the testing of prognostic criteria and therapeutics agents targeting NOTCH1 (28, 66).
Materials and Methods
Cell Lines and Isolation of Human B-Cell Subsets. MO1043 cells (29) were cultured in Iscove's Modified Dulbecco's Medium (Life Technologies) supplemented with 20% (vol/vol) FBS (Sigma-Aldrich), penicillin (100 U/mL), and streptomycin (100 μg/mL). The identity of the cell line was verified by CN analysis using the Genome-Wide Human SNP Array 6.0 (Affymetrix), as previously reported (3) . HEK 293T cells were cultured in Dulbecco's Modified Eagle Medium (Life Technologies) with 10% (vol/vol) FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. OP9 and OP9-DL1 cells were grown in Minimum Essential Medium Alpha Medium (Corning) supplemented with 20% (vol/vol) FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM glutamine (Thermo Fisher Scientific) (54) . Human GC B cells, naive B cells, and memory B cells were isolated from reactive tonsils as described previously (23) . Compound E was obtained from Enzo Life Sciences and used at a final concentration of 500 nM to 1 μM in DMSO vehicle.
Protein Extraction and Immunoblot Analysis. Whole-cell extracts were obtained using Nonidet P-40 lysis buffer (150 mM NaCl, 1.5% (vol/vol) Nonidet P-40, 50 mM Tris·HCl pH 8.0, 2 mM EDTA pH 8.0) supplemented with proteinase inhibitor mixture (Sigma-Aldrich), according to a previously described protocol (67) . Protein lysates were resolved on 4-12% Tris-Glycine gels (Novex, Life Technologies). Subcellular fractionation was performed as previously described (68) . Samples were incubated with primary antibodies overnight at 4°C. The following primary antibodies were used: rabbit monoclonal anticleaved NOTCH1 (clone D3B8, Cell Signaling Technology), mouse monoclonal anti-MYC (clone 9E10, Santa Cruz), mouse monoclonal anti-BCL6 (clone GI191E/A8, Cell Marque), rabbit monoclonal anti-HA (clone C29F4, Cell Signaling Technology), mouse monoclonal anti-β-actin (clone AC-15, Sigma), rabbit polyclonal anti-β-tubulin (H-235, Santa Cruz). Horseradish peroxidase-conjugated secondary antibodies and ECL or West Dura reagent (Thermo Fisher Scientific) were used for signal detection.
Immunofluorescence Analysis. Immunofluorescence analysis of ICN1, AID, and CD20 was performed on formalin-fixed paraffin-embedded material from human tonsils and primary peripheral blood CLL cells according to standard procedures using the following antibodies: rabbit monoclonal anticleaved NOTCH1 (clone D3B8, Cell Signaling Technology), rat monoclonal anti-AID (clone mAID-2, eBioscience), and mouse monoclonal anti-C20 (clone L26, Thermo Fisher) (69).
ChIP. MO1043-ICN1-HA cells (cells induced to express ICN1-HA with 1 μg/mL of doxycycline for 36 h) were cross-linked with 1% formaldehyde for 10 min at room temperature, quenched by the addition of glycine to a final concentration of 0.125 M and frozen at −80°C. Cross-linked chromatin was fragmented by sonication with the Bioruptor sonicator (Diagenode) to achieve fragment sizes of ∼200-500 bp using the following sonication buffer: 10 mM Tris·HCl pH 8.0, 100 mM NaCl, 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0, 0.1% Na-Deoxycholate, and 0.5% N-lauroylsarcosine. Sheared chromatin was incubated overnight with 10 μL of NOTCH1 antisera (70), 4 μg of antibodies to H3K27Ac (Active Motif, cat#39133) or H3K4me3 (Abcam, cat#ab8580), or 2 μg of antibodies to H3K4me1 (Abcam, cat#ab8895) or H3K27me3 (Active Motif, cat#39157) (ENCODE Project: genome.ucsc.edu/ENCODE/antibodies.html). Protein A magnetic beads were added for 4 h at 4°C, followed by sequential washes at increasing stringency and reverse cross-linking. After RNase and proteinase K treatment, ChIP DNA was purified using the MiniElute Reaction Clean Up Kit (Qiagen) and quantified by Quant-iT PicoGreen dsDNA Reagent (Life Technologies). Validation via quantitative PCR analysis (qChIP-PCR) was performed with the Power SYBR green PCR Master Mix using the 7300 Real Time PCR system (Applied Biosystems). Oligonucleotides used for qChIP-PCR are listed in Dataset S13.
ChIP-Seq Library Preparation and Illumina Sequencing. ChIP-Seq libraries were constructed starting from 4 ng of ChIP or Input DNA as reported in BlecherGonen et al. (71) . Libraries were quantified using the KAPA SYBR FAST Universal qPCR Kit (KAPA Biosystems), normalized to 10 nM, pooled, and sequenced with the Illumina HiSEq. 2000 instrument as single-end 100-bp reads.
ChIP-Seq Analysis. Sequencing data were acquired through the default Illumina pipeline using Casava v1.8. Reads were aligned to the human genome (UCSC hg19) using the Bowtie2 aligner v2.1.0 (72), allowing up to two mismatches to cope with human variation. Duplicate reads (i.e., reads of identicallength mapping to exactly the same genomic locations) were removed with SAM tools v0.1.19 using the rmdup option (73) . Read counts were normalized to the total number of reads aligned in a library (reads per million). Peak detection was done using the ChIPseeqer v2.0 algorithm (74) , enforcing a minimum fold-change of 2 between ChIP and input reads, a minimum peak width of 100 bp, and a minimum distance of 100 bp between peaks. The threshold for statistical significance of peaks was set at 10 −5 for NOTCH1, and 10 −15 for H3K4me1, H3K4me3, and H3K27Ac (Dataset S2). Peaks within 1 kb of centromeric or telomeric regions were removed. H3K4me1 and H3K27Ac peaks were stitched together into regions if located within ±2 kb and ±12.5 kb of each other, respectively, unless they started within a 2-kb window around the TSS. H3K27me3 peaks were called using the RSEG algorithm (75) with 100-bp bin size; only peaks above 5 kb in size were considered.
Motif Enrichment Analysis. Regions within 200 bp of the center of each binding site were searched for motifs from the TRANSFAC 2010 Database. Motifs were represented as position weighted matrices. Using a moving window, motifs were scored against a reference DNA sequence using a log odds ratio comparing the motif's score to a hypothetical score where every base is equally probable. Motifs scoring higher than a given threshold were considered as potentially bound in a location. To determine enrichment in a set of peaks/ locations a hypergeometric model was used comparing motifs bound in the peaks to a GC and length controlled set of random genomic sequences. DNA Extraction, IGHV Mutational Status, and Sanger Sequencing of NOTCH1. Genomic DNA was extracted with the QIAamp DNA Mini Kit (Qiagen) and verified for integrity by gel electrophoresis. IGHV mutational status was performed as previously described (3, 13) . The NOTCH1 gene portion encoding the PEST domain and the 3′UTR of the NOTCH1 gene were screened by Sanger targeted sequencing, as previously reported (3, 7).
Gene-Expression Profiling of Human Mature B-Cell Subsets. Raw expression values of GeneChip Human Genome U133 Plus 2.0 (Affymetrix) data from normal mature B-cell subsets were normalized using the Robust Multiarray Averaging algorithm in GenePattern (https://www.broadinstitute.org/cancer/software/ genepattern/), and multiple probes corresponding to the same gene were collapsed to a single probe based on the maximum t-statistic/maximum SD.
RNA Extraction, cDNA Synthesis, and Quantitative Real-Time PCR. Total RNA was extracted from primary CLL cases with the RNeasy Mini Kit (Qiagen) with on-column DNase treatment. cDNA synthesis was performed using the SuperScript First-Strand Synthesis System (Life Technologies), according to the manufacturer's instructions. The ABsolute QPCR SYBR green mix (Thermo Scientific) was used to amplify specific cDNA fragments with the oligonucleotides listed in Dataset S13, in the 7300 Real-Time PCR system (Applied Biosystems). Data were analyzed by the change-in-threshold (2 −ΔΔCT ) method (77), using GAPDH as a housekeeping reference gene.
RNA-Sequencing of ICN1-HA and Control eGFP MO1043 Cells and Primary CLL Cases. Four MO1043-ICN1-HA and 4 MO1043-eGFP replicates and 49 primary CLL cases were subjected to RNA-Sequencing. Briefly, poly-A pull-down was performed to enrich mRNAs from total RNA samples and libraries were prepared using the Illumina TruSeq RNA prep kit and sequenced using the Illumina HiSeq.2000 instrument at the Columbia Genome Center. MO1043-ICN1-HA and MO1043-eGFP samples were multiplexed to obtain an average of 33,022,292 singleend 100-bp reads per sample; primary CLL samples were multiplexed to obtain an average of 61,266,691 paired-end 100-bp reads per sample (Dataset S3). Real-time analysis (Illumina) was used for base calling and bcl2fastq (v1.8.4) for converting BCL to fastq format, coupled with adaptor trimming. Reads were mapped to the reference genome (Human: NCBI/build37.2) using Tophat (v2.0.4) with 4 mismatches (-read-mismatches = 4) and 10 maximum multiple hits (-max-multihits = 10) (78). The relative abundance of genes was assessed using cufflinks (v2.0.2) with default settings (79) . Hierarchical clustering of MO1043-ICN1-HA and -eGFP profiles was performed using the Pearson correlation average linkage, filtering for genes with a minimum log 2 -transformed expression value of 5 and a minimum SD of 1. Genes differentially expressed between MO1043-ICN1-HA and -eGFP profiles were determined by an unpaired unequal variance two-tailed Student's t test using a FDR ≤ 0.001 (after Benjamini-Hochberg correction) (80) . For visualization of gene-expression intensity, expression data were converted to z-scores.
GSEA. Gene-expression profile data from mature B cells, MO1043-ICN1-HA and MO1043-eGFP cells, and from primary CLL cases were analyzed for enrichment in NOTCH1-related gene sets with GSEA-2.0 and 1,000 phenotype permutations (27) . Enrichments were considered significant with a P < 0.05 after correction for multiple hypothesis.
Functional Categories and Pathways Analyses of the NOTCH1-Regulated Genes. Genes directly regulated by NOTCH1 in CLL were assigned to functional categories or annotated pathways using the publicly available bioinformatic tool DAVID 2008 6.7 (Database for Annotation, Visualization and Integrated Discovery, https://david-d.ncifcrf.gov) and the Molecular Signatures Database from the Broad Institute (MSigDBv5.1, CP Geneset, https://www.broadinstitute. org/gsea/msigdb/index.jsp). Only pathways relevant for B-cell biology, based on current knowledge, were selected for further discussion.
Statistical Analyses. Statistical analysis was performed using the GraphPad Prism 5 software (GraphPad Software). The specific test adopted for each analysis is described in each figure legend.
